Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer
- 9 November 1996
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 348 (9037), 1279-1281
- https://doi.org/10.1016/s0140-6736(96)04471-6
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primatesBlood, 1996
- Megakaryocyte growth and development factor ameliorates carboplatin- induced thrombocytopenia in miceBlood, 1995
- The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.Proceedings of the National Academy of Sciences, 1994
- Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpICell, 1994
- c-Mpl ligand is a humoral regulator of megakaryocytopoiesisNature, 1994
- Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivoNature, 1994
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994
- Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironmentBlood, 1994
- The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose CarboplatinNew England Journal of Medicine, 1993
- EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPYThe Lancet, 1988